12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bosulif bosutinib regulatory update

EMA's CHMP issued a positive opinion recommending conditional approval of an MAA from Pfizer for Bosulif bosutinib to treat adults with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) previously treated with >=1 tyrosine kinase...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >